We advised the lead placement agents

Davis Polk advised the lead placement agents in connection with a private placement of shares of common stock of Solid Biosciences Inc. and, in lieu of common stock, pre-funded warrants to purchase shares of common stock.

Solid intends to use the proceeds from the offering to fund ongoing pipeline development programs, business development activities, working capital and other general corporate purposes.

Headquartered in Charlestown, Massachusetts, Solid is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including SGT-003 for Duchenne muscular dystrophy (Duchenne), SGT-212 for Friedreich’s ataxia (FA), SGT-501 for catecholaminergic polymorphic ventricular tachycardia (CPVT), SGT-601 for TNNT2-mediated dilated cardiomyopathy and additional fatal, genetic cardiac diseases.

The Davis Polk capital markets team included partners Deanna L. Kirkpatrick and Yasin Keshvargar and associate Sofia Sitterson. All members of the Davis Polk team are based in the New York office.

Copy link to share post